Identifying Rheumatic Disease Patients at High Risk and Requiring Shielding During the COVID-19 Pandemic

Overview

Journal Clin Med (Lond)

Specialty General Medicine

Date 2020 May 7

PMID 32371418

Citations 24

Authors

Elizabeth Price

Elizabeth MacPhie

Lesley Kay

Peter Lanyon

Bridget Griffiths

Christopher Holroyd

Abhishek Abhishek

Taryn Youngstein

Kathryn Bailey

Jacqui Clinch

Muddassir Shaikh

Ali Rivett

Affiliations

Soon will be listed here.

Abstract

Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England.

Citing Articles

Digital Health for Equitable Rheumatic Care: Integrating Real-World Experiences to Guide Policy Pathways.

Santosa A, Li J, Tan T Healthcare (Basel). 2025; 13(4).

PMID: 39997313 PMC: 11855621. DOI: 10.3390/healthcare13040438.

Communication to promote and support physical distancing for COVID-19 prevention and control.

Ryan R, Silke C, Parkhill A, Virgona A, Merner B, Hurley S Cochrane Database Syst Rev. 2023; 10:CD015144.

PMID: 37811673 PMC: 10561351. DOI: 10.1002/14651858.CD015144.

Association between SYVN1 and SEL1 genetic polymorphisms and remission in rheumatoid arthritis patients treated with TNF-α inhibitors: a machine learning approach.

Kim W, Yeon H, Kim J, Kim J, Kim J, Kim H Immunol Res. 2023; 71(5):709-716.

PMID: 37119459 DOI: 10.1007/s12026-023-09382-4.

Exploring the longer-term impact of the COVID-19 pandemic on physical and mental health of people with inflammatory rheumatic diseases: a cross-sectional survey.

Hider S, Muller S, Gray L, Manning F, Brooks M, Heining D Clin Rheumatol. 2023; 42(7):1903-1909.

PMID: 36882533 PMC: 9990972. DOI: 10.1007/s10067-023-06565-0.

Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic.

Sahebari M, Mirfeizi Z, Hashemzadeh K, Salavati Nik E, Gholampoor Shamkani N Arch Bone Jt Surg. 2022; 10(11):964-968.

PMID: 36561225 PMC: 9749122. DOI: 10.22038/ABJS.2022.60064.2959.

References

Wagner M, Earley A, Webster A, Schmid C, Balk E, Uhlig K . Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015; (12):CD007746. PMC: 10986644. DOI: 10.1002/14651858.CD007746.pub2. View

Dennison E, Packham J, Hyrich K . The BSRBR-RA at 15 years. Rheumatology (Oxford). 2016; 55(12):2093-2095. PMC: 5061081. DOI: 10.1093/rheumatology/kew053. View

Decarriere G, Barnetche T, Combe B, Gaujoux-Viala C, Lukas C, Morel J . Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2020; 73(6):873-884. DOI: 10.1002/acr.24195. View

Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C . Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020; 36(7):e3319. PMC: 7228407. DOI: 10.1002/dmrr.3319. View

Davies R, Southwood T, Kearsley-Fleet L, Lunt M, Hyrich K . Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol. 2015; 67(9):2487-94. PMC: 5049649. DOI: 10.1002/art.39197. View

Rutherford A, Patarata E, Subesinghe S, Hyrich K, Galloway J . Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018; 57(6):997-1001. DOI: 10.1093/rheumatology/key023. View

Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H . Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6:16. PMC: 7078228. DOI: 10.1038/s41421-020-0156-0. View

Alfaro-Lara R, Espinosa-Ortega H, Arce-Salinas C . Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin (Engl Ed). 2017; 15(3):133-139. DOI: 10.1016/j.reuma.2017.07.020. View

Galloway J, Hyrich K, Mercer L, Dixon W, Fu B, Ustianowski A . Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with.... Rheumatology (Oxford). 2010; 50(1):124-31. PMC: 3105607. DOI: 10.1093/rheumatology/keq242. View

10.

Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva E . Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018; 20(1):285. PMC: 6307151. DOI: 10.1186/s13075-018-1780-z. View

11.

Wang Z, Bao H, Ji Y . A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis. Medicine (Baltimore). 2020; 99(8):e19193. PMC: 7034717. DOI: 10.1097/MD.0000000000019193. View

12.

Subesinghe S, Rutherford A, Byng-Maddick R, Hyrich K, Benjamin Galloway J . Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2018; 57(4):651-655. DOI: 10.1093/rheumatology/kex469. View

13.

Thong K, Chan T . Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis. Lupus. 2019; 28(3):334-346. DOI: 10.1177/0961203319829817. View

14.

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

15.

Waki D, Nishimura K, Tokumasu H, Kadoba K, Mukoyama H, Saito R . Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study. Medicine (Baltimore). 2020; 99(8):e19173. PMC: 7034627. DOI: 10.1097/MD.0000000000019173. View

16.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

17.

Youssef J, Novosad S, Winthrop K . Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am. 2015; 42(1):157-76, ix-x. PMC: 4751577. DOI: 10.1016/j.rdc.2015.08.004. View

18.

Stockman L, Bellamy R, Garner P . SARS: systematic review of treatment effects. PLoS Med. 2006; 3(9):e343. PMC: 1564166. DOI: 10.1371/journal.pmed.0030343. View

19.

Kang Y . Mortality Rate of Infection With COVID-19 in Korea From the Perspective of Underlying Disease. Disaster Med Public Health Prep. 2020; 14(3):384-386. PMC: 7156566. DOI: 10.1017/dmp.2020.60. View

20.

Hazlewood G, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C . Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. Cochrane Database Syst Rev. 2016; (8):CD010227. PMC: 7087436. DOI: 10.1002/14651858.CD010227.pub2. View